Antenatal Corticosteroids for Late-Preterm Infants : A Decision-Analytic and Economic Analysis

Abstract EN

Objectives.

Antenatal corticosteroids (ACS) are not routinely administered to patients at risk for delivery between 34 and 36 6/7 weeks.

Our objective was to determine whether ACS are cost-effective for late-preterm infants at risk for imminent preterm delivery.

We hypothesized that the preferred strategy <36 weeks would include ACS while the preferred strategy ≥36 weeks would not.

Methods.

We performed decision-analytic and cost-effectiveness analyses to determine whether ACS was cost-effective at 34, 35, and 36 weeks.

We conducted a literature review to determine probability, utility, and cost estimates absent of patient-level data.

Base-case cost-effectiveness analysis, univariable sensitivity analysis, and Monte Carlo simulation were performed.

A threshold of $100,000/QALY was considered cost-effective.

Results.

The incremental cost-effectiveness ratio favored the administration of a full course of ACS at 34, 35, and 36 weeks ($62,888.25/QALY, $64,425.67/QALY, and $64,793.71/QALY, resp.).

A partial course of ACS was not cost-effective.

While ACS was the consistently dominant strategy for acute respiratory outcomes, all models were sensitive to changes in variables associated with chronic respiratory disease.

Conclusions.

Our findings suggest that the administration of ACS to patients at risk of imminent delivery 34-36 weeks could significantly reduce the cost and acute morbidity associated with late-preterm birth.